Gov. Martin O’Malley

ANAPOLIS, Md. — Maryland Gov. Martin O’Malley praised Emergent BioSolutions for its upcoming expansion in East Baltimore during his online economic update released Nov. 19.

Fuad El-Hibri

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced that it has completed the acquisition of a 55,000-square-foot manufacturing facility from MdBio Foundation and the land on which the facility stands from the city of Baltimore.

R. Don Elsey

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced Nov. 5 its financial results for the third quarter and nine months ended Sept. 30.

Anthrax

WASHINGTON — Federal advisers said more data is needed to judge the effectiveness of Human Genome Sciences' anthrax treatment compared with existing anti-bacterial drugs, The Associated Press reported Oct. 27.

A U.S. government formulation designed to defend against a bio-terrorism attack is available for commercial use to eliminate the H1N1 Virus, MRSA, SARS and other dangerous bacterium and pathogens found in hospitals, schools and public institutions.

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced that the U.S. Department of Health and Human Services issued an additional amendment to its request for proposal for an anthrax recombinant protective antigen (rPA) vaccine.

ROCKVILLE, Md. — The Department of Health and Human Services requested that bidders in the competitive range for a contract to develop an rPA vaccine candidate submit its product development plans to the FDA for review in advance of an award.

National Institute of Allergy and Infectious Diseases

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced March 17, 2009, that the Phase I/II clinical trial for its anthrax immune globulin (AIG) therapeutic candidate has commenced with the initial treatment given to the first subject.

Anthrax

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced July 31, 2008, that it has submitted a proposal in response to a request by the U.S. Department of Health and Human Services for a recombinant protective antigen anthrax vaccine (rPA).

Anthrax

ROCKVILLE, Md. —Emergent BioSolutions Inc. announced that on March 6, 2008, it completed the acquisition of a group of anthrax monoclonal antibodies from AVANIR Pharmaceuticals, including Avanir’s lead product candidate, AVP-21D9.

Anthrax

GAITHERSBURG, Md. — Emergent BioSolutions Inc. announced that the FDA has issued a final order confirming that the company’s anthrax vaccine, BioThrax, is safe and effective for immunization against infection, regardless of the route of exposure.